Mastodawn

Italy probes Biogen over alleged attempts to block Sandoz’s MS biosimilar and limit competition in natalizumab drugs.

💊💉 #natalizumab
SmPC for Tysabri 150 mg solution for injection in pre-filled syringe has been updated with changes to sections 4.6 Fertility, pregnancy and lactation; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 6.4 Special precautions for storage; 10. Date of revision of the text on 8 November 2024.
🌐 https://www.medicines.org.uk/emc/product/12443/smpc
Change log: https://www.medicines.org.uk/emc/product/12443/smpc/history

Tysabri 150 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) by Biogen Idec Ltd

💊💉 #natalizumab
SmPC for Tysabri 150 mg solution for injection in pre-filled syringe has been updated with changes to sections 5.1 Pharmacodynamic properties; 6.3 Shelf life; 10. Date of revision of the text on 15 July 2024.
🌐 https://www.medicines.org.uk/emc/product/12443/smpc
Change log: https://www.medicines.org.uk/emc/product/12443/smpc/history

Tysabri 150 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) by Biogen Idec Ltd

I'm now keeping an eye on: The SmPC for Tysabri 150 mg solution for injection in pre-filled syringe

🏭Biogen Idec Ltd

I will let you know if it changes.

Tysabri 150 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) by Biogen Idec Ltd

I'm now keeping an eye on: The SmPC for Tyruko 300 mg concentrate for solution for infusion

🏭Sandoz Limited

I will let you know if it changes.

Tyruko 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by Sandoz Limited